MRO Magazine

Australian Hyaluronic Acid Viscosupplementation Market Report 2016 Featuring Genzyme (Sanofi) & Bioventus (Smith & Nephew) – Research and Markets

June 20, 2016
By Business Wire News


Research and Markets has announced the addition of the “Australian Market Report for Hyaluronic Acid Viscosupplementation” report to their offering.

Hyaluronic acids (HAs) are naturally occurring biopolymer fluids found in the joints that help cushion them from wear. Sufferers of osteoarthritis are deficient in these fluids. One of the treatment options for these patients is HA viscosupplement injections.

Viscosupplements are injectable products that come in three varieties of injection regimens. The exact mechanism of their action is unclear, but the therapy works by increasing the viscoelasticity of the synovial fluid, thereby reducing friction between the joints. The immediate short-term benefit appears to be mainly pain relief, more so than actual healing, although this does allow for long-term improvements in mobility and range of motion. The products are appropriate in cases where the patient has failed to respond to pharmacological or steroid therapy and there is no contraindication to injection therapy. The effectiveness of these products has mainly been established for the knee joints, and has not yet been very well established for use in other joints of the body.

Viscoelasticity is a property describing the ability to absorb shock. Fluids that have a high degree of this property provide greater resistance to sudden shocks and impacts than they do to loads that are applied gradually. In an osteoarthritic knee, the cartilage wears faster than it can repair itself. The shock-absorbing quality of hyaluronic acid products reduces this wear on the articular cartilage, allowing it to heal. The product itself does not remain in the joint space long after injection, as it lasts only hours or days. The therapeutic benefit, however, can last up to half a year, indicating that there may be some element of

anti-inflammatory action or stimulation of the body’s natural ability to replenish the joint fluid. Because there is no pharmacologic action associated with the treatment, these products are classified as medical devices in the majority of circumstances. In India, however, most HA products are classified as drugs.

Key Topics Covered:

1. Full Suite Executive Summary

1.1 Australian Orthopedic Biomaterials Market Overview

1.2 Competitive Analysis

1.3 Market Trends

1.4 Key Market Developments

1.5 Procedures Numbers

1.6 Markets Included

1.7 Key Report Updates

1.8 Version History

2. Research Methodology

2.1 Research Scope

2.2 9-Step Methodology

3. Hyaluronic Acid Viscosupplementation Market

3.1 Introduction

3.2 Market Overview

3.2.1 Hyaluronic Acid Viscosupplementation Market By Injection Cycle

3.3 Market Analysis And Forecast

3.3.1 Total Hyaluronic Acid Viscosupplementation Market

3.3.2 Total Hyaluronic Acid Viscosupplementation Market By Injection Cycle Single-Injection Hyaluronic Acid Viscosupplementation Market Three-Injection Hyaluronic Acid Viscosupplementation Market

3.4 Drivers And Limiters

3.4.1 Market Drivers

3.4.2 Market Limiters

3.5 Competitive Analysis

Companies Mentioned

  • Genzyme (Sanofi)
  • Bioventus (Smith & Nephew)

For more information visit

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Orthopedic Devices, Organic Acids, Food Additive Chemicals